RET (V804M)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.V804M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 99.9% | 0.1% | 93.43 |
| 2 | Selpercatinib | 99.8% | 0.2% | 96.72 |
| 3 | Alpelisib | 99.8% | 0.2% | 97.22 |
| 4 | Sunitinib | 99.8% | 0.2% | 91.73 |
| 5 | Entrectinib | 99.7% | 0.3% | 93.69 |
| 6 | Sorafenib | 99.2% | 0.8% | 96.72 |
| 7 | Gilteritinib | 99.0% | 1.0% | 88.97 |
| 8 | Quizartinib | 98.8% | 1.1% | 99.50 |
| 9 | Tivozanib | 98.4% | 1.6% | 92.42 |
| 10 | Fedratinib | 98.3% | 1.7% | 96.21 |
| 11 | Ponatinib | 98.1% | 1.9% | 78.23 |
| 12 | Futibatinib | 98.0% | 2.0% | 98.48 |
| 13 | Repotrectinib | 97.3% | 2.7% | 84.21 |
| 14 | Alectinib | 94.1% | 5.9% | 95.49 |
| 15 | Brigatinib | 92.9% | 7.1% | 82.96 |
| 16 | Avapritinib | 92.7% | 7.3% | 97.73 |
| 17 | Nintedanib | 90.6% | 9.4% | 90.23 |
| 18 | Upadacitinib | 90.2% | 9.8% | 97.98 |
| 19 | Fostamatinib | 88.7% | 11.3% | 96.74 |
| 20 | Erdafitinib | 88.3% | 11.7% | 95.71 |
| 21 | Ripretinib | 88.0% | 12.0% | 92.95 |
| 22 | Tenalisib | 87.3% | 12.7% | 97.98 |
| 23 | Defactinib | 87.0% | 13.0% | 92.68 |
| 24 | Baricitinib | 86.9% | 13.1% | 97.99 |
| 25 | Deucravacitinib | 85.4% | 14.6% | 98.99 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 99.9% | 100.0% | -0.1% |
| Selpercatinib | 99.8% | 100.0% | -0.2% |
| Alpelisib | 99.8% | 99.6% | +0.2% |
| Sunitinib | 99.8% | 97.2% | +2.6% |
| Entrectinib | 99.7% | 99.6% | +0.1% |
| Sorafenib | 99.2% | 94.0% | +5.3% |
| Gilteritinib | 99.0% | 100.0% | -1.0% |
| Quizartinib | 98.8% | — | — |
| Tivozanib | 98.4% | 99.7% | -1.3% |
| Fedratinib | 98.3% | 99.9% | -1.6% |
| Ponatinib | 98.1% | 100.0% | -1.9% |
| Futibatinib | 98.0% | 97.7% | +0.4% |
| Repotrectinib | 97.3% | — | — |
| Alectinib | 94.1% | 97.8% | -3.7% |
| Brigatinib | 92.9% | 94.9% | -1.9% |
| Avapritinib | 92.7% | — | — |
| Nintedanib | 90.6% | 100.0% | -9.4% |
| Upadacitinib | 90.2% | — | — |
| Fostamatinib | 88.7% | — | — |
| Erdafitinib | 88.3% | 94.7% | -6.4% |
| Ripretinib | 88.0% | — | — |
| Tenalisib | 87.3% | 98.5% | -11.3% |
| Defactinib | 87.0% | — | — |
| Baricitinib | 86.9% | — | — |
| Deucravacitinib | 85.4% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
| PRAD | Prostate | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.2ms